Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adocia Announces Initiation of a Clinical Trial on its Combination of Glargine and Lispro

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
This phase I/II clinical trial on Type I diabetics seeks to compare the performance of this Combo based on insulin Glargine with HumalogMix®.

Adocia has announced that it has launched the first clinical trial of its innovative formulation combining insulin Glargine (Lantus®, Sanofi), the gold-standard of long acting insulin, with a fast-acting insulin analog, insulin Lispro (Humalog®, Eli Lilly). This unique combination is made possible thanks to the BioChaperone® technology developed by Adocia, which makes insulin Glargine compatible with fast-acting insulin analogs.

This clinical trial aims to demonstrate that the combination could offer diabetic patients improved glycemic control compared to a Premix of insulin analog such as HumalogMix, based on insulin Lispro (Eli Lilly), or NovoMix®, based on insulin Aspart (Novo Nordisk).

Hence, pharmacodynamic and pharmacokinetic profiles of the combination BioChaperone Glargine/Lispro will be compared to the pharmacodynamic and pharmacokinetic profiles of HumalogMix in a cross-over design on 20 Type I diabetic patients under a euglycemic clamp. The first patients of this double-blind study conducted in Germany have already been treated.

Today, Type I and Type II diabetic patients requiring intensive insulin therapy have two treatment options: either a Premix, which is a formulation of a single insulin with both fast and long actions, or an association of two products, a long-acting insulin and a fast-acting insulin. The current gold-standard of long-acting insulin is Lantus, which generated USD 6.5 billion in 2012.

Premix products, NovoMix (Novo Nordisk) and HumalogMix (Eli Lilly), ease everyday life for diabetics, who can manage their glycaemia using only one product injected twice daily. These Premix have been commercialized for more than ten years and generate annual revenues of more than USD 2.3 billion, with significant growth in emerging markets. However, these products put patients at higher risk of hypoglycemia compared to separate injections of Lantus and a fast-acting analog insulin.

“There is a real need to provide patients using Lantus and a fast-acting insulin with the simplicity afforded by Premix products, as well as to offer Premix-using patients the greater medical efficacy obtained with Lantus, a real gold-standard,” said Gerard Soula, Adocia’s CEO. This combination could therefore extend Glargine’s market potential towards the Premix market. This Combo based on insulin Glargine, an insulin off-patent in 2015, has been internationally patented in 2012.”

“Adocia’s BioChaperone proprietary technology allows for a clear and stable solution of insulin Glargine and a fast-acting analog insulin, two products that are not compatible under natural conditions,” said Olivier Soula, deputy general director and R&D director at Adocia. “In this clinical trial, we are testing one of the potential combinations but alternative combinations, namely with insulin Glulisine (Apidra®, Sanofi) and insulin Aspart (NovoLog®, Novo Nordisk) have also been validated in preclinics.”

Results from this study are expected during the first quarter of 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adocia Confirms Positive Clinical Results for its BioChaperone® Combo
BioChaperone Combo is the first combination based on insulin glargine to show a fast and long action in type I diabetic patients.
Friday, March 21, 2014
Adocia Launches Phase IIa Clinical Trial for its Ultra-fast Acting Formulation of Analog Insulin
The aim is to confirm on type I diabetic patients the positive results obtained during phase I.
Tuesday, January 07, 2014
Adocia Announces Revenues of EUR 4.7 M for the Third Quarter of 2013
The company maintained available cash at EUR 22.7 M.
Thursday, October 24, 2013
Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
Study on healthy volunteers of a formulation using Adocia’s BioChaperone® platform showed fast onset of action, excellent local tolerance, absence of pain and low inter-patient variability.
Wednesday, March 16, 2011
Scientific News
Immune-Cell Traps May Aid Cancer Metastasis
Study suggests cancer cells can induce neutrophils to release traps which the cells use to capture pathogens.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Blood-brain Barrier on a Chip
Researchers from Vanderbilt University have developed a microfluidic device to study the blood-brain barrier.
Uncovering Cerebral Malaria’s Deadly Agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
Parkinson's Disease Linked to Microbiome
Scientists have discovered a link between intestinal bacteria and Parkinson's disease.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Possible Treatment for Rare Vascular Disease
Researchers manage to reverse hereditary haemorrhagic telangiectasia in mice, if successful in humans it could lead to improved treatment for the disease.
Cracking the Code of a Deadly Virus
Researchers have exploited weaknesses in VEEV's genetic code, creating a far less deadly variant.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!